Mairs and Power's ABBV Position Overview
Mairs and Power (via Mairs & Power INC) currently holds 46,456 shares of AbbVie Inc. (ABBV) worth $10.61 M, representing 0.10% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 51 quarters.
Based on 13F filings since 2013, Mairs and Power has maintained a long-term strategic position in ABBV, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2013, adding 11,507 shares. Largest reduction occurred in Q3 2017, reducing 56,819 shares.
Analysis based on 13F filings available since 2013 Q2
Mairs and Power's AbbVie (ABBV) Holding Value Over Time
Track share changes against reported price movement
Quarterly AbbVie (ABBV) Trades by Mairs and Power
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -965 | Reduce 2.03% | 46,456 | $228.49 |
| Q3 2025 | +348 | Add 0.74% | 47,421 | $231.54 |
| Q2 2025 | +5,111 | Add 12.18% | 47,073 | $185.62 |
| Q1 2025 | -3,808 | Reduce 8.32% | 41,962 | $209.52 |
| Q4 2024 | -976 | Reduce 2.09% | 45,770 | $177.70 |
| Q3 2024 | +395 | Add 0.85% | 46,746 | $197.48 |
| Q2 2024 | +2,719 | Add 6.23% | 46,351 | $171.52 |
| Q1 2024 | -3,652 | Reduce 7.72% | 43,632 | $182.10 |
| Q4 2023 | -698 | Reduce 1.45% | 47,284 | $154.97 |
| Q3 2023 | -1,591 | Reduce 3.21% | 47,982 | $149.06 |
| Q2 2023 | -3,338 | Reduce 6.31% | 49,573 | $134.73 |
| Q1 2023 | -92 | Reduce 0.17% | 52,911 | $159.37 |
| Q4 2022 | -910 | Reduce 1.69% | 53,003 | $161.61 |
| Q3 2022 | +3,025 | Add 5.94% | 53,913 | $134.22 |
| Q2 2022 | +1,107 | Add 2.22% | 50,888 | $153.16 |
| Q1 2022 | -2,613 | Reduce 4.99% | 49,781 | $162.11 |
| Q4 2021 | +1,716 | Add 3.39% | 52,394 | $135.40 |
| Q3 2021 | +247 | Add 0.49% | 50,678 | $107.88 |
| Q2 2021 | -1,811 | Reduce 3.47% | 50,431 | $112.65 |
| Q1 2021 | -15,221 | Reduce 22.56% | 52,242 | $108.23 |
| Q4 2020 | -675 | Reduce 0.99% | 67,463 | $107.16 |
| Q3 2020 | -891 | Reduce 1.29% | 68,138 | $87.59 |
| Q2 2020 | -1,152 | Reduce 1.64% | 69,029 | $98.18 |
| Q1 2020 | -5,746 | Reduce 7.57% | 70,181 | $76.19 |
| Q4 2019 | +127 | Add 0.17% | 75,927 | $88.55 |
| Q3 2019 | -3,224 | Reduce 4.08% | 75,800 | $75.73 |
| Q2 2019 | -5,572 | Reduce 6.59% | 79,024 | $72.72 |
| Q1 2019 | -14,545 | Reduce 14.67% | 84,596 | $80.59 |
| Q4 2018 | -16,527 | Reduce 14.29% | 99,141 | $92.19 |
| Q3 2018 | -55,309 | Reduce 32.35% | 115,668 | $94.58 |
| Q2 2018 | -3,834 | Reduce 2.19% | 170,977 | $92.65 |
| Q1 2018 | -7,221 | Reduce 3.97% | 174,811 | $94.65 |
| Q4 2017 | -16,093 | Reduce 8.12% | 182,032 | $96.71 |
| Q3 2017 | -56,819 | Reduce 22.29% | 198,125 | $88.86 |
| Q2 2017 | -1,398 | Reduce 0.55% | 254,944 | $72.51 |
| Q1 2017 | -8,023 | Reduce 3.03% | 256,342 | $65.16 |
| Q4 2016 | -2,088 | Reduce 0.78% | 264,365 | $62.62 |
| Q3 2016 | -2,700 | Reduce 1.00% | 266,453 | $63.07 |
| Q2 2016 | +962 | Add 0.36% | 269,153 | $61.91 |
| Q1 2016 | +1,380 | Add 0.52% | 268,191 | $57.12 |
| Q4 2015 | -125 | Reduce 0.05% | 266,811 | $59.24 |
| Q3 2015 | -1,840 | Reduce 0.68% | 266,936 | $54.41 |
| Q2 2015 | -3,250 | Reduce 1.19% | 268,776 | $67.19 |
| Q1 2015 | +4,189 | Add 1.56% | 272,026 | $58.54 |
| Q4 2014 | +4,000 | Add 1.52% | 267,837 | $65.44 |
| Q3 2014 | -479 | Reduce 0.18% | 263,837 | $57.76 |
| Q2 2014 | -5,620 | Reduce 2.08% | 264,316 | $56.44 |
| Q1 2014 | -9,758 | Reduce 3.49% | 269,936 | $51.40 |
| Q4 2013 | +11,507 | Add 4.29% | 279,694 | $52.81 |
| Q3 2013 | -11,279 | Reduce 4.04% | 268,187 | $44.73 |
| Q2 2013 | +279,466 | Add 0.00% | 279,466 | $41.34 |
Mairs and Power's AbbVie Investment FAQs
Mairs and Power first purchased AbbVie Inc. (ABBV) in Q2 2013, acquiring 279,466 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Mairs and Power has held AbbVie Inc. (ABBV) for 51 quarters since Q2 2013.
Mairs and Power's largest addition to AbbVie Inc. (ABBV) was in Q2 2013, adding 279,466 shares worth $11.55 M.
According to the latest 13F filing for Q4 2025, Mairs and Power's firm, Mairs & Power INC, owns 46,456 shares of AbbVie Inc. (ABBV), valued at approximately $10.61 M.
As of the Q4 2025 filing, AbbVie Inc. (ABBV) represents approximately 0.10% of Mairs and Power's publicly disclosed stock portfolio, making it one of their key holdings.
Mairs and Power's peak holding in AbbVie Inc. (ABBV) was 279,694 shares, as reported at the end of Q4 2013.